GHIF Announcements
March 30, 2021
Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding.
December 17, 2020
Univercells Holding raises €70 million in Series C Financing
Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics.
October 13, 2020
Access Bio’s Covid-19 test receives approval
FDA Grants EUA For Access Bio’s Lateral Flow COVID-19 Antigen Test
September 9, 2020
Alydia receives FDA clearance for postpartum bleeding device
Vacuum-Induced Uterine Tamponade Device for Postpartum Hemorrhage
August 10, 2020
Australian TGA approves Atomo’s Rapid COVID-19 Antibody Test
Australia’s Therapeutic Goods Administration (TGA) approved Sydney-based Atomo’s rapid SARS-CoV-2 antibody blood test for use by medical professionals in Australia.
July 30, 2020
Industry Veterans Will Lead Planned Launch of Device Designed to Provide a Safe, Rapid Solution for Abnormal Postpartum Uterine Bleeding
June 19, 2020
Milestone Reflects Merck’s Commitment to Accelerate SARS-CoV-2 Vaccine Program
May 22, 2020
GeneDrive (formery Epistem) receives CE mark for SARS COV-2 PCR kit
Genedrive said Friday that it has received the CE mark for its Genedrive 96 SARS-CoV-2 Kit and is making it available for sale in the European Union, including the UK, and other countries that accept the mark.
Apr 16, 2020
GHIF portfolio company Atomo Diagnostics Limited listed today on Australian Securities Exchange
Net proceeds to be used for expanded production of rapid test devices for COVID-19 testing
October 23, 2018
Carl Zeiss Meditec announces acquisition of IanTech to expand its cataract surgery portfolio
Carl Zeiss Meditec today announced it has entered into an agreement to acquire IanTECH. Headquartered in Reno, Nevada, IanTECH is a privately held company focused on technology solutions for micro-interventional cataract surgery.
20 September 2018
GHIF Leads $10 Million Series B Financing for Alydia Health
Financing Will Support U.S. Pivotal Study of Device Designed to Provide a Safe, Natural, and Rapid Solution for Postpartum Hemorrhage
16 July 2018
GHIF Leads €16 Million Series B Financing for Univercells
Investment proceeds will support commercialization of the company’s breakthrough biologics manufacturing technology
4 January 2018
GHIF Leads €10 Million Series C Financing for Themis Bioscience
Proceeds will support the further development of the company’s chikungunya vaccine candidate, which recently reported encouraging interim Phase II study data
13 July 2017
GHIF and Visionary Venture Fund Back Iantech
Iantech will use the funding to further R&D and commercial efforts for its miLOOP technology, which has the potential to significantly improve global efforts to address cataract-induced visual impairment
31 January 2017
PATH, Clarus, and GHIF Announce $25 Million Anthelmintic Collaboration
Innovative financing arrangement will improve treatment of intestinal worms, affecting more than 1 billion people globally
21 December 2016
KfW Development Bank Publishes GHIF Project Update
Report indicates GHIF is performing against original impact investment objectives
30 March 2016
Access Bio Added to GHIF Portfolio as 6th Investment
$8 million of convertible note proceeds will finance the purchase and installation of new manufacturing equipment for Access Bio’s rapid diagnostic test products
13 January 2016
GHIF Makes $6 Million Loan to Atomo Diagnostics
The investment will support continued rollout of Atomo’s award-winning AtomoRapid™ HIV test and launch of an affordable HIV self-test offering unmatched performance
8 January 2016
GHIF-Backed EuBiologics Earns WHO Endorsement for Euvichol
WHO prequalification of Euvichol will double the availability of approved oral cholera vaccine in 2016
8 March 2015
If approved, moxidectin is expected to significantly accelerate the eradication of this terrible neglected disease
27 August 2014
GHIF Leads $7.5 Million Investment into Cholera Vaccine Manufacturer
Korean biopharmaceutical company commits to manufacture a new and improved presentation of the vaccine at a target price of $1.00 per dose for public sector buyers
22 July 2014
GHIF Invests in Epistem to Finance New TB Diagnostic
Investment will support the roll-out of Epistem’s Genedrive® molecular diagnostic platform as the company’s tuberculosis assay enters pivotal field trials in key developing world locations
GHIF in the News
23 October 2018
Carl Zeiss Meditec to Acquire IanTECH, Inc. to expand its portfolio in cataract surgery
ZEISS to enhance its portfolio of Surgical Ophthalmology solutions, further positioning the Company as a global innovation leader and solution provider in the full space of ophthalmology.
22 July 2018
Australian not-for-profit wins unprecedented approval for blindness drug
An Australian company has won unprecedented US approval for a new drug to treat the second most common preventable cause of blindness in the world. In the process, Medicines Development for Global Health became the first not-for-profit company in the world to register a treatment with the US Food and Drug Administration.
7 March 2018
Global health coalition inks agreement to develop vaccines for MERS, Lassa fever
The Coalition for Epidemic Preparedness Innovations said this week that it has awarded its first contract, an agreement with an Austrian biotech company [GHIF-backed Themis Bioscience] to develop vaccines to protect against Middle East respiratory syndrome, or MERS, and Lassa fever.
17 January 2018
A new powerful drug to combat river blindness
Recently published phase 3 study results in The Lancet show that GHIF-backed moxidectin is a promising treatment for onchocerciasis, with the potential to “reduce parasite transmission between treatment rounds more than ivermectin could, thus accelerating progress towards elimination.”
10 January 2018
Oral cholera vaccine in lighter plastic packaging hits market
The International Vaccine Institute said Tuesday that the world’s first oral cholera vaccine packaged in plastic tube vials is now available for purchase. The vaccine, named Euvichol-Plus, was developed by South Korean drug-maker EuBiologics, with financing for the plastic tube program provided by the Global Health Investment Fund.
25 May 2017
This fund seeks a traditional return and grantlike impact for global health R&D
Staff at the Bill & Melinda Gates Foundation and J.P. Morgan said they hope the Global Health Investment Fund will demonstrate that it is possible to generate social impact, reduce costs to health care systems and deliver financial returns to investors at the same time.
13 December 2016 :: Barron’s Penta Daily
How to Make Money With Impact Investments
“Social-impact investing might often be about the intangible benefits provided to society. When it comes to your portfolio, however, you want to be sure the financial returns delivered aren’t intangible, but very real.”
29 November 2016 :: Inside Philanthropy
Can Investing in Rapid Self-Testing Disrupt the HIV/AIDS Mortality Curve?
Earlier this year, the Global Health Investment Fund (GHIF) announced that it was making a $6 million loan to Atomo Diagnostics, a point-of-care diagnostics company improving rapid testing platforms
5 October 2016 :: Bloomberg Radio
The Bloomberg Advantage: LaBelle on Social Impact on Medicine
Curt Labelle, Managing Partner at the Global Health Investment Fund, discussing working to save lives, while also lowering healthcare costs in the developing world
2 October 2013 :: Jamie Dimon
Innovating and Investing for Life-Saving Impact
GHIF will give individual and institutional investors their first ever opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries
23 September 2013 :: The Globe and Mail
Billionaires team up to fight disease in developing world
Public-private partnerships are increasingly the norm when it comes to tackling vexing global health challenges
23 September 2013 :: JPMorgan Chase & Co.
New Investment Fund Will Advance Late-Stage Vaccines and other Global Health Technologies
JPMorgan Chase, the Bill & Melinda Gates Foundation and partners announce successful capital raise for first-of-its-kind investment product